Journal of Clinical Oncology
Articles in this Issue
Safety and efficacy of pucotenlimab combined with standard chemotherapy regimens in the neoadjuvant treatment of pediatric patients with intermediate or high-risk rhabdomyosarcoma: A phase I/II study.
10038 Background: Previously, we defined the pathological complete response rate (pCR) for pediatric patients with intermediate or high-risk rhabdomyosarc...
Sex-based disparities in HPV-related cancer outcomes: Insights into social determinants of health.
10529 Background: Human papillomavirus (HPV) is the most common sexually transmitted infection and a leading cause of several cancers. Research suggests t...
Diffuse large B-cell lymphoma patients with early post diagnosis mortality at a quaternary care center.
e23078 Background: Treatment of diffuse large B-cell lymphoma (DLBCL) has seen significant advances over the last decade, including CAR-T, ADCs and bispec...
Transarterial chemoembolization combined with atezolizumab plus bevacizumab versus transarterial chemoembolization combined with lenvatinib plus sintilimab as first-line therapy for advanced hepatocellular carcinoma.
e16223 Background: Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic therapy as first-line treatment for advanced hep...
Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx regimen in patients with treatment-naïve extranodal natural killer/T cell lymphoma (TN-ENKTL): A multicenter, open-label, single-arm, phase II study (SCENT-2 trial).
7006 Background: ENKTL is a highly aggressive NHL with a higher incidence in Asia. P-GemOx regimen is one of standard first-line treatment with mildly tox...
A Breast Cancer Hub initiative, conducting door-to-door cervical cancer awareness, symptom identification in 11,277 women, and providing screening and treatment support in underserved villages of Assam, India, from February 2020 to April 2024.
e13522 Background: In 2022, India had the second-highest incidence of cervical cancer globally, with 127,356 new cases, and the highest number of related...
Treatment intensification in veterans with metastatic prostate cancer.
e13785 Background: Treatment intensification with androgen receptor pathway inhibitors (ARPIs) or chemotherapy in addition to traditional androgen depriva...
5-year survival outcomes after perioperative pembrolizumab (pembro) in patients with human papillomavirus (HPV)-unrelated, locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A multi-center, two-cohort, phase 2 trial.
6079 Background: A phase 2 trial (NCT02296684) demonstrated that perioperative pembro added to standard of care (SOC) surgery/adjuvant radiation-based the...
Ethnic differences in nonalcoholic fatty liver disease (NAFLD) among women with early-stage breast cancer receiving endocrine therapy.
e12524 Background: NAFLD is a metabolic comorbidity increasingly recognized in oncology populations.Hormone receptor-positive (HR+) breast cancer (BC) is...
Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy.
2513 Background: Although immune checkpoint inhibitors (ICIs) have transformed cancer treatment, many patients still develop primary or acquired resistanc...
Immunotherapy-induced DKA: Are sugars on the rise?
e14602 Background: Type 1 Diabetes Mellitus (T1DM) is a serious side effect of Immune Checkpoint Inhibitors (ICIs), which typically presents as Diabetic K...
Geographic access to triple negative breast cancer (TNBC) clinical trials: Are trials located near Black women?
1111 Background: Despite recent treatment advances, TNBC has a poor prognosis relative to other breast cancer subtypes. Black women in the U.S. are more l...
Using preprocedural clinical factors and CT radiomics to predict hepatocellular carcinoma response to yttrium-90 resin microspheres selective internal radiation therapy: A real-world study in China.
e16179 Background: To evaluate the predictive potential of preprocedural clinical factors and CT radiomic features for treatment response in hepatocellula...
Breast cancer recurrence and mortality among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
10066 Background: Survivors of childhood cancer are at high risk for developing subsequent breast cancer (BC). However, BC recurrence risk and survival af...
Systemic mastocytosis: Statistics and impact of secondary malignancy on survival.
e22559 Background: Systemic mastocytosis (SM) is a rare disease characterized by clonal mast cell accumulation. The incidence of systemic mastocytosis is...
Primary results of a phase 2 study of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer.
5511 Background: Locally advanced vulvar cancer is a rare but lethal disease more common in underserved populations. In contrast to other gynecologic canc...
Insights from a 21-year analysis of mortality due to hypertension and esophageal cancer in the United States.
e16131 Background: Hypertension (HTN) is one of the most common non-communicable diseases globally, affecting nearly half of all adults in the United Stat...
Integrative clinico-genomic evaluation of the human epidermal growth factor receptor 2 (HER2) in urothelial cancer (UC).
4569 Background: HER2-directed therapy with trastuzumab deruxtecan is now FDA approved for UC with high HER2 expression. The interaction between HER2 expr...
Sensitivity of age and family history (FH) criteria for determining pancreatic cancer (PC) surveillance (PCS) eligibility among individuals with hereditary PC risk.
10500 Background: PCS for individuals with pathogenic/likely pathogenic germline variants (PGVs) predisposing to PC is associated with earlier stage at di...
How to improve efficiency in IO clinical trials: Comprehensive analysis of a decade long reporting bias among 1867 trials.
e14661 Background: Immunotherapy has transformed cancer treatment, offering curative potential while sparing patients from aggressive therapies like chemo...
Methylation-specific epigenetic and ctDNA biomarkers in prognosis of advanced NSCLC.
e20554 Background: Methylation specific epigenetic biomarkers and circulating tumor DNA (ctDNA) are emerging as important prognostic biomarkers in the adv...
Clinical and genomic characteristics of HER2-IHC 0 (membrane staining +) breast cancer and implications for T-DXd therapy.
e13158 Background: The clinical benefit of T-DXd in advanced breast cancer with hormone receptor-positive (HR+), HER2-IHC 0 with membrane staining (MS+) t...
A phase 2 study of lanreotide as a therapy for pheochromocytomas (PCs) and paragangliomas (PGs).
10612 Background: PCs arise from adrenomedullary chromaffin cells, while PGs are derived from extra-adrenal chromaffin cells of the sympathetic paraverteb...
Phase II study of epacadostat (INCB024360) added to preoperative chemoradiation in patients with locally advanced rectal cancer.
TPS3648 Background: Indoleamine 2,3-dioxygenase 1 (IDO1) metabolizes tryptophan along the kynurenine pathway and is recognized as a potent suppressor of t...
Geographic and demographic disparities in lung cancer prevalence among young adults: A SEER-based analysis.
e22552 Background: Lung cancer in young adults (<55 years) is rare but has gained attention as a special clinical entity. This population often present...